Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00498979 · ClinicalTrials.gov registry record · Phase 1
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
A Phase 1 study of Stage IV Melanoma, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT00498979: Completed Phase 1 study of Stage IV Melanoma, sponsored by Case Comprehensive Cancer Center.
NCT00498979 is a Phase 1 study of Stage IV Melanoma that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 22 participants, below the 45-participant average among 13 other Stage IV Melanoma trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00498979, a Phase 1 study of Stage IV Melanoma, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Sodium stibogluconate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma and other cancers. Drugs used in chemotherapy, such as cisplatin, vinblastine, and dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sodium stibogluconate and interferon alfa-2b together with combination chemotherapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of sodium stibogluconate when given together with interferon alfa-2b, cisplatin, vinblastine, and dacarbazine in treating patients with advanced melanoma or other cancer.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG vinblastine
- DRUG dacarbazine
- BIOLOGICAL recombinant interferon alfa-2b
- DRUG sodium stibogluconate
Study Locations (1)
Ohio
- Cleveland Clinic Taussig Institute, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2007-05 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
What the finished NCT00498979 record still lists
NCT00498979 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 45-participant average among 13 other Stage IV Melanoma trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Stage IV Melanoma appearing as the primary indexed condition, and to 5 interventions - of which cisplatin is the first listed.
NCT00498979 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00498979 about?
NCT00498979 is a clinical study titled "Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers". RATIONALE: Sodium stibogluconate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma and other cancers. Drugs used in chemotherapy, such as cisplatin, vinblastine, a...
What is the current status of trial NCT00498979?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2007-05. Estimated completion is 2012-01.
What conditions does trial NCT00498979 study?
This clinical trial studies the following conditions: Stage IV Melanoma.
What interventions are being tested in trial NCT00498979?
The interventions under investigation include: cisplatin (DRUG), vinblastine (DRUG), dacarbazine (DRUG), recombinant interferon alfa-2b (BIOLOGICAL), sodium stibogluconate (DRUG).
Who is sponsoring clinical trial NCT00498979?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00498979 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00498979's enrollment target sits among peer trials
22 13th of 13 higher than 1 of 13 other Stage IV Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage IV Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
ACTIVE NOT RECRUITING · Phase 1
-
Decitabine in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
COMPLETED · Phase 1
-
E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
COMPLETED · Phase 1
-
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
COMPLETED · Phase 1
-
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia